<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542058</url>
  </required_header>
  <id_info>
    <org_study_id>Cardio-oncology study</org_study_id>
    <nct_id>NCT03542058</nct_id>
  </id_info>
  <brief_title>Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.</brief_title>
  <acronym>SATRACD</acronym>
  <official_title>Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uganda Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to describe the burden of subclinical anthracycline therapy&#xD;
      related cardiac dysfunction( ATRCD) by applying international guideline on Uganda cancer&#xD;
      patient and to evaluate the significance of treating subclinical ATRCD with carvedilol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific objectives:&#xD;
&#xD;
        1. To determine the incidence of subclinical ATRCD among cancer patient who receives&#xD;
           Anthracycline therapy.&#xD;
&#xD;
        2. To compare the changes of GLS value between hypertension and non hypertension cancer&#xD;
           patient at the competition of the anthracycline therapy.&#xD;
&#xD;
        3. To determine the correlation of conventional echocardiograghy(ECHO) parameters (MAPSE,&#xD;
           S') with GLS, and their ability to diagnose or rule out subclinical ATRCD.&#xD;
&#xD;
        4. To determine the correlation of oxidative stress with cardiac function(GLS value) in&#xD;
           patients who receives Anthracycline therapy&#xD;
&#xD;
        5. To describe the cardioprotective effect of carvedilol in patients with subclinical&#xD;
           ATRCD.&#xD;
&#xD;
      METHODS This is going to be two prospective cohort study (cohort 1 and 2) followed by a&#xD;
      randomized controlled trial (cohort 3).&#xD;
&#xD;
      To achieve objective 1 ,3 and 4, Cohort 1 will consecutively recruit 300 adult non&#xD;
      hypertension cancer patients who are going to receive anthracycline therapy.&#xD;
&#xD;
      To achieve objective 2, Cohort 2 will consecutively recruit 53 adult hypertension cancer&#xD;
      patients (group H) and 106 non hypertension controls (group N) who are going to receive&#xD;
      anthracycline therapy. Controls will be recruited from cohort 1 by systemic sampling(&#xD;
      Choosing the 2nd patients as they are enrolled in cohort 1).&#xD;
&#xD;
      Patient's demographic data, cancer diagnosis, dosage of anthracyclin, past medical history,&#xD;
      symptoms, physical examinations, ECG, ECHO and laboratory data will be collected at the&#xD;
      baseline. Patient follow up will be performed at the completion of the chemo therapy, and&#xD;
      6month thereafter. Data of symptoms, physical examinations, ECG, ECHO and blood test will be&#xD;
      collected at each visit. The end point will be the development of subclinical ATRCD.&#xD;
&#xD;
      To achieve objective 5, patients in Cohort 1, who are diagnosed with Subclinical ATRCD will&#xD;
      be recruited into cohort 3 and being randomized into group T(carvedilol treatment group) and&#xD;
      group C( control, none treatment group).Systemic randomization will be used in Cohort 3: ever&#xD;
      second eligible patient will be recruited in group C. Patients in cohort 3 will be followed&#xD;
      up for 6month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>6 months</time_frame>
    <description>This will be measured by mean GLS(Global Longitudinal strain) value.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chemotherapy Related Cardiac Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study participant will not receive any cardiac medication, apart from standard cancer care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Carvedilol Denk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between and include 18 and 50 years.&#xD;
&#xD;
          2. Newly diagnosed cancer patients who develop subclinical ATRCD during cardiac follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who has been taking carvedilol prior to the study&#xD;
&#xD;
          2. Patient who self report to be allergic to carvedilol&#xD;
&#xD;
          3. Systolic blood pressure &lt; 90mmHg&#xD;
&#xD;
          4. Heart Rate &lt; 50 beat per minute&#xD;
&#xD;
          5. Patient who is asthmatic or has chronic obstructive lung disease&#xD;
&#xD;
          6. Pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Sliwa, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hatter Institute for Cardiovascular Disease in Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feriel Azibani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hatter Institute for Cardiovascular Disease in Africa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wan Zhu Zhang, Master</last_name>
    <phone>+256774431009</phone>
    <email>raniox@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmy Okello, PhD</last_name>
    <phone>+775522284</phone>
    <email>emmyoks@gmail.com</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

